Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Drug Deliv ; 15(10): 1449-1458, 2018.
Article in English | MEDLINE | ID: mdl-30058488

ABSTRACT

BACKGROUND: It is well documented in the scientific literature that high blood pressure can lead to cardiovascular disease. Untreated hypertension has clinical consequences such as coronary artery disease, stroke or kidney failure. Diltiazem hydrochloride (DH), a calcium-channel blocker, and perindopril erbumine (PE), an inhibitor of the angiotensin converting enzyme are used for the management of hypertension. OBJECTIVE: This project will examine the effect of microneedle rollers on the transport of DH and PE across pig ear skin. The use of the transcutaneous route of administration reduces and in sometimes eliminates the trauma and pain associated with injections. Furthermore, there is increased patient compliance. The purpose of this project was to study the effect of stainless steel microneedles on the transdermal delivery of DH and PE. METHOD: We utilized vertical Franz diffusion cells to study in vitro transport of DH and PE across microneedle- treated pig ear skin. Confocal laser scanning microscopy (CLSM) was used to characterize microchannel depth. Transdermal flux values were determined from the slope of the linear portion of the cumulative amount versus time curve. RESULTS: There was a 113.59-fold increase in the transdermal permeation of DH following the application of microneedle roller compared to passive diffusion. CONCLUSION: In the case of PE, there was an 11.99-fold increase in the drug transport across pig skin following the application of microneedle rollers in comparison with passive diffusion. Student's t-test and Mann-Whitney's rank sum test were used to determine statistically significant differences between experimental and control groups.


Subject(s)
Antihypertensive Agents/pharmacokinetics , Diltiazem/administration & dosage , Diltiazem/pharmacokinetics , Needles , Perindopril/administration & dosage , Perindopril/pharmacokinetics , Skin Absorption , Skin/metabolism , Administration, Cutaneous , Animals , Antihypertensive Agents/administration & dosage , Diffusion , Drug Delivery Systems , Stainless Steel/chemistry , Swine
2.
Mol Ther ; 26(7): 1685-1693, 2018 07 05.
Article in English | MEDLINE | ID: mdl-29914756

ABSTRACT

Treatment of myocardial infarction (MI) with bone marrow cells (BMCs) improves post-MI cardiac function in rodents. However, clinical trials of BMC therapy have been less effective. While most rodent experiments use young healthy donors, patients undergoing autologous cell therapy are older and post-MI. We previously demonstrated that BMCs from aged and post-MI donor mice are therapeutically impaired, and that donor MI induces inflammatory changes in BMC composition including reduced levels of B lymphocytes. Here, we hypothesized that B cell alterations in bone marrow account for the reduced therapeutic potential of post-MI and aged donor BMCs. Injection of BMCs from increasingly aged donor mice resulted in progressively poorer cardiac function and larger infarct size. Flow cytometry revealed fewer B cells in aged donor bone marrow. Therapeutic efficacy of young healthy donor BMCs was reduced by depletion of B cells. Implantation of intact or lysed B cells improved cardiac function, whereas intact or lysed T cells provided only minor benefit. We conclude that B cells play an important paracrine role in effective BMC therapy for MI. Reduction of bone marrow B cells because of age or MI may partially explain why clinical autologous cell therapy has not matched the success of rodent experiments.


Subject(s)
Aging/physiology , B-Lymphocytes/cytology , Bone Marrow Cells/cytology , Bone Marrow/physiology , Heart/physiology , Myocardial Infarction/physiopathology , Animals , Bone Marrow Transplantation/methods , Cell- and Tissue-Based Therapy/methods , Flow Cytometry/methods , Male , Mice , Mice, Inbred C57BL
3.
J Am Heart Assoc ; 5(8)2016 07 27.
Article in English | MEDLINE | ID: mdl-27464788

ABSTRACT

BACKGROUND: Despite public awareness that tobacco secondhand smoke (SHS) is harmful, many people still assume that marijuana SHS is benign. Debates about whether smoke-free laws should include marijuana are becoming increasingly widespread as marijuana is legalized and the cannabis industry grows. Lack of evidence for marijuana SHS causing acute cardiovascular harm is frequently mistaken for evidence that it is harmless, despite chemical and physical similarity between marijuana and tobacco smoke. We investigated whether brief exposure to marijuana SHS causes acute vascular endothelial dysfunction. METHODS AND RESULTS: We measured endothelial function as femoral artery flow-mediated dilation (FMD) in rats before and after exposure to marijuana SHS at levels similar to real-world tobacco SHS conditions. One minute of exposure to marijuana SHS impaired FMD to a comparable extent as impairment from equal concentrations of tobacco SHS, but recovery was considerably slower for marijuana. Exposure to marijuana SHS directly caused cannabinoid-independent vasodilation that subsided within 25 minutes, whereas FMD remained impaired for at least 90 minutes. Impairment occurred even when marijuana lacked cannabinoids and rolling paper was omitted. Endothelium-independent vasodilation by nitroglycerin administration was not impaired. FMD was not impaired by exposure to chamber air. CONCLUSIONS: One minute of exposure to marijuana SHS substantially impairs endothelial function in rats for at least 90 minutes, considerably longer than comparable impairment by tobacco SHS. Impairment of FMD does not require cannabinoids, nicotine, or rolling paper smoke. Our findings in rats suggest that SHS can exert similar adverse cardiovascular effects regardless of whether it is from tobacco or marijuana.


Subject(s)
Air Pollution/adverse effects , Endothelium, Vascular/drug effects , Marijuana Smoking/adverse effects , Smoke/adverse effects , Animals , Coronary Circulation/drug effects , Female , Nitric Oxide/metabolism , Nitroglycerin/pharmacology , Peripheral Vascular Diseases/etiology , Peripheral Vascular Diseases/physiopathology , Rats, Sprague-Dawley , Time Factors , Vasodilation/drug effects , Vasodilator Agents/pharmacology
4.
J Am Heart Assoc ; 5(1)2016 Jan 06.
Article in English | MEDLINE | ID: mdl-26738788

ABSTRACT

BACKGROUND: Circulating angiogenic cells (CACs) are peripheral blood cells whose functional capacity inversely correlates with cardiovascular risk and that have therapeutic benefits in animal models of cardiovascular disease. However, donor age and disease state influence the efficacy of autologous cell therapy. We sought to determine whether age or coronary artery disease (CAD) impairs the therapeutic potential of CACs for myocardial infarction (MI) and whether the use of ex vivo gene therapy to overexpress endothelial nitric oxide (NO) synthase (eNOS) overcomes these defects. METHODS AND RESULTS: We recruited 40 volunteers varying by sex, age (< or ≥45 years), and CAD and subjected their CACs to well-established functional tests. Age and CAD were associated with reduced CAC intrinsic migration (but not specific response to vascular endothelial growth factor, adherence of CACs to endothelial tubes, eNOS mRNA and protein levels, and NO production. To determine how CAC function influences therapeutic potential, we injected the 2 most functional and the 2 least functional CAC isolates into mouse hearts post MI. The high-function isolates substantially improved cardiac function, whereas the low-function isolates led to cardiac function only slightly better than vehicle control. Transduction of the worst isolate with eNOS cDNA adenovirus increased NO production, migration, and cardiac function of post-MI mice implanted with the CACs. Transduction of the best isolate with eNOS small interfering RNA adenovirus reduced all of these capabilities. CONCLUSIONS: Age and CAD impair multiple functions of CACs and limit therapeutic potential for the treatment of MI. eNOS gene therapy in CACs from older donors or those with CAD has the potential to improve autologous cell therapy outcomes.


Subject(s)
Coronary Artery Disease/enzymology , Endothelial Progenitor Cells/enzymology , Endothelial Progenitor Cells/transplantation , Myocardial Infarction/surgery , Neovascularization, Physiologic , Nitric Oxide Synthase Type III/metabolism , Nitric Oxide/metabolism , Stem Cell Transplantation/methods , Adult , Aged , Animals , Case-Control Studies , Cell Movement , Cells, Cultured , Coculture Techniques , Coronary Artery Disease/diagnosis , Disease Models, Animal , Female , Humans , Male , Mice, SCID , Middle Aged , Myocardial Infarction/enzymology , Myocardial Infarction/genetics , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Nitric Oxide Synthase Type III/genetics , Phenotype , RNA Interference , Recovery of Function , Regeneration , Signal Transduction , Time Factors , Transduction, Genetic , Transfection
5.
PLoS One ; 8(4): e61413, 2013.
Article in English | MEDLINE | ID: mdl-23630585

ABSTRACT

Pleiotrophin (PTN) is a growth factor with both pro-angiogenic and limited pro-tumorigenic activity. We evaluated the potential for PTN to be used for safe angiogenic gene therapy using the full length gene and a truncated gene variant lacking the domain implicated in tumorigenesis. Mouse myoblasts were transduced to express full length or truncated PTN (PTN or T-PTN), along with a LacZ reporter gene, and injected into mouse limb muscle and myocardium. In cultured myoblasts, PTN was expressed and secreted via the Golgi apparatus, but T-PTN was not properly secreted. Nonetheless, no evidence of uncontrolled growth was observed in cells expressing either form of PTN. PTN gene delivery to myocardium, and non-ischemic skeletal muscle, did not result in a detectable change in vascularity or function. In ischemic hindlimb at 14 days post-implantation, intramuscular injection with PTN-expressing myoblasts led to a significant increase in skin perfusion and muscle arteriole density. We conclude that (1) delivery of the full length PTN gene to muscle can be accomplished without tumorigenesis, (2) the truncated PTN gene may be difficult to use in a gene therapy context due to inefficient secretion, (3) PTN gene delivery leads to functional benefit in the mouse acute ischemic hindlimb model.


Subject(s)
Carrier Proteins/genetics , Cytokines/genetics , Genetic Therapy , Ischemia/therapy , Muscle, Skeletal/blood supply , Peptide Fragments/genetics , Animals , Carrier Proteins/metabolism , Cell Movement , Cell Transformation, Neoplastic/metabolism , Cells, Cultured , Coronary Vessels/pathology , Cytokines/metabolism , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum Stress , Hindlimb/blood supply , Hindlimb/pathology , Human Umbilical Vein Endothelial Cells/physiology , Humans , Male , Mice , Mice, Nude , Mice, SCID , Muscle, Skeletal/pathology , Myoblasts/metabolism , Myoblasts/transplantation , Myocardium/pathology , Myocytes, Smooth Muscle/physiology , Neovascularization, Physiologic , Peptide Fragments/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...